Home  »  Hot Stocks   »  NeuroOne Medical Technologies Corporation (NMTC) S...

NeuroOne Medical Technologies Corporation (NMTC) Shares Up Despite Recent Market Volatility

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s stock price has increased by 8.92 compared to its previous closing price of 1.57. but the company has seen a -6.04% decline in its stock price over the last five trading sessions.

Is It Worth Investing in NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Right Now?

and a 36-month beta value of 0.67. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


The average price predicted for NeuroOne Medical Technologies Corporation (NMTC) by analysts is $2.63, which is $0.91 above the current market price. The public float for NMTC is 13.46M, and at present, short sellers hold a 0.80% of that float. On March 16, 2023, the average trading volume of NMTC was 89.06K shares.

NMTC’s Market Performance

NMTC stock saw a decrease of -6.04% in the past week, with a monthly decline of -16.99% and a quarterly a decrease of -18.18%. The volatility ratio for the week is 14.15%, and the volatility levels for the last 30 days are 11.28% for NeuroOne Medical Technologies Corporation (NMTC). The simple moving average for the last 20 days is 2.53% for NMTC stock, with a simple moving average of 15.80% for the last 200 days.

Analysts’ Opinion of NMTC

Many brokerage firms have already submitted their reports for NMTC stocks, with Craig Hallum repeating the rating for NMTC by listing it as a “Hold.” The predicted price for NMTC in the upcoming period, according to Craig Hallum is $2 based on the research report published on March 29th of the previous year 2022.

NMTC Trading at 12.22% from the 50-Day Moving Average

After a stumble in the market that brought NMTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.03% of loss for the given period.

Volatility was left at 11.28%, however, over the last 30 days, the volatility rate increased by 14.15%, as shares sank -1.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.50% upper at present.

During the last 5 trading sessions, NMTC fell by -6.04%, which changed the moving average for the period of 200-days by +58.33% in comparison to the 20-day moving average, which settled at $1.6668. In addition, NeuroOne Medical Technologies Corporation saw 42.50% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NMTC starting from McClurg Ronald W., who purchase 10,000 shares at the price of $1.02 back on Jun 15. After this action, McClurg Ronald W. now owns 67,000 shares of NeuroOne Medical Technologies Corporation, valued at $10,219 using the latest closing price.

McClurg Ronald W., the Chief Financial Officer of NeuroOne Medical Technologies Corporation, purchase 14,000 shares at $1.06 during a trade that took place back on Jun 10, which means that McClurg Ronald W. is holding 57,000 shares at $14,781 based on the most recent closing price.

Stock Fundamentals for NMTC

Current profitability levels for the company are sitting at:

  • -441.84 for the present operating margin
  • +88.59 for the gross margin

The net margin for NeuroOne Medical Technologies Corporation stands at -471.67. Equity return is now at value -86.00, with -74.20 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.93.


To sum up, NeuroOne Medical Technologies Corporation (NMTC) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.